Cargando…

Retraction Note: LAMP2 expression dictates azacytidine response and prognosis in MDS/AML

Detalles Bibliográficos
Autores principales:	Dubois, Alix, Furstoss, Nathan, Calleja, Anne, Zerhouni, Marwa, Cluzeau, Thomas, Savy, Coline, Marchetti, Sandrine, Hamouda, Mohamed Amine, Boulakirba, Sonia, Orange, François, Lacas-Gervais, Sandra, Karsenti, Jean-Michel, Mounier, Nicolas, Tamburini, Jérôme, Puissant, Alexandre, Luciano, Frederic, Jacquel, Arnaud, Auberger, Patrick, Robert, Guillaume
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Retraction Note
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449876/ https://www.ncbi.nlm.nih.gov/pubmed/32665699 http://dx.doi.org/10.1038/s41375-020-0969-8

Ejemplares similares

ATP-competitive Plk1 inhibitors induce caspase 3-mediated Plk1 cleavage and activation in hematopoietic cell lines
por: Dufies, Maeva, et al.
Publicado: (2017)

BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients
por: Cluzeau, Thomas, et al.
Publicado: (2012)

IL-34 and CSF-1 display an equivalent macrophage differentiation ability but a different polarization potential
por: Boulakirba, Sonia, et al.
Publicado: (2018)

Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2019)

Reprogramming monocyte-derived macrophages through caspase inhibition
por: Chaintreuil, Paul, et al.
Publicado: (2021)

Total genomic alteration as measured by SNP-array-based molecular karyotyping is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine
por: Cluzeau, T, et al.
Publicado: (2013)

Phenotypic and genotypic characterization of azacitidine-sensitive and resistant SKM1 myeloid cell lines
por: Cluzeau, Thomas, et al.
Publicado: (2014)

The generation, activation, and polarization of monocyte-derived macrophages in human malignancies
por: Chaintreuil, Paul, et al.
Publicado: (2023)

All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to Ponatinib
por: Cassuto, Ophélie, et al.
Publicado: (2012)

Drug Resistance in Hematological Malignancies
por: Auberger, Patrick, et al.
Publicado: (2020)

Differentiation inducing factor 3 mediates its anti-leukemic effect through ROS-dependent DRP1-mediated mitochondrial fission and induction of caspase-independent cell death
por: Dubois, Alix, et al.
Publicado: (2016)

The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells
por: Hamouda, Mohamed-Amine, et al.
Publicado: (2014)

P705: AZACYTIDINE THERAPY REVERTS MDS-ASSOCIATED CHANGES IN MSC-DERIVED EXTRACELLULAR MATRIX
por: Bains, Amanpreet, et al.
Publicado: (2023)

Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype
por: Sallman, David A., et al.
Publicado: (2016)

A new posttranslational regulation of REDD1/DDIT4 through cleavage by caspase 3 modifies its cellular function
por: Puissant, A, et al.
Publicado: (2014)

Azacytidine Failure Revisited: an Appraisal Based on Real-Life Data from the MDS Registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS)
por: Kotsianidis, Ioannis, et al.
Publicado: (2019)

Complications of 5-azacytidine: Three cases of severe ischemic colitis in elderly patients with myelodysplastic syndrome
por: MELCHARDT, THOMAS, et al.
Publicado: (2013)

Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells
por: Dufies, Maeva, et al.
Publicado: (2011)

DNMT1 expression partially dictates 5-Azacytidine sensitivity and correlates with RAS/MEK/ERK activity in gastric cancer cells
por: Chen, Zhangqian, et al.
Publicado: (2023)

Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation
por: Ørskov, Andreas D., et al.
Publicado: (2015)

Prognostic impact of peripheral blood Wilms’ tumour 1 mRNA expression levels in response to azacytidine in MDS: A single-centre analysis
por: Maeda, Tomoya, et al.
Publicado: (2020)

Chaperone-Mediated Autophagy and Its Emerging Role in Hematological Malignancies
por: Robert, Guillaume, et al.
Publicado: (2019)

Azacytidine impairs NK cell activity in AML and MDS patients undergoing MRD-based pre-emptive treatment after allogeneic stem cell transplantation
por: Schönefeldt, C, et al.
Publicado: (2013)

Development of an Oral Form of Azacytidine: 2′3′5′Triacetyl-5-Azacytidine
por: Ziemba, Amy, et al.
Publicado: (2011)

BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice
por: Hamouda, Mohamed-Amine, et al.
Publicado: (2016)

Implication and Regulation of AMPK during Physiological and Pathological Myeloid Differentiation
por: Jacquel, Arnaud, et al.
Publicado: (2018)

Azacytidine Treatment for VEXAS Syndrome
por: Raaijmakers, Marc H. G. P., et al.
Publicado: (2021)

Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN
por: Mestrum, Stefan G. C., et al.
Publicado: (2020)

Azacytidine (Vidaza®) in the treatment of myelodysplastic syndromes
por: Raj, Kavita, et al.
Publicado: (2006)

Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells
por: Imanishi, Satoshi, et al.
Publicado: (2017)

ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS
por: Sallman, David A, et al.
Publicado: (2017)

The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5‐azacytidine: Results from the Hellenic 5‐azacytidine registry
por: Diamantopoulos, Panagiotis, et al.
Publicado: (2019)

ATS MD’s in 2016
por: Fartoukh, Stephane, et al.
Publicado: (2016)

Software needs for MDs
por: Ruggiero, F
Publicado: (1993)

LHC MDS For 2018
por: Tomás, R, et al.
Publicado: (2019)

Bogus "M.Ds."
por: Karnik, C. H.
Publicado: (1929)

Cytogenetic effect of 5-azacytidine in patients with hematological malignancies
por: Tsuda, Jessica Romy, et al.
Publicado: (2011)

CNS Involvement in AML Patient Treated with 5-Azacytidine
por: Vasilatou, Diamantina, et al.
Publicado: (2014)

Suppressing nonsense—a surprising function for 5-azacytidine
por: Shao, Ada, et al.
Publicado: (2014)

The Dictator
Publicado: (1906)

Cannot write session to /tmp/vufind_sessions/sess_d3s3i3f8894m02e1igufere5ep